PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE
Clinical trials for PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE explained in plain language.
Never miss a new study
Get alerted when new PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE trials appear
Sign up with your email to follow new studies for PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug shows promise for Alzheimer's psychosis in Long-Term safety trial
Disease control Recruiting nowThis study looks at the long-term safety of a drug called KarXT for people with Alzheimer's disease who also have psychosis (hallucinations or delusions). It is for people who have already completed a previous KarXT study. The goal is to see if KarXT is safe and tolerable over 52…
Matched conditions: PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE
Phase: PHASE3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Disease control
Last updated May 26, 2026 12:02 UTC
-
Hope for Alzheimer's patients: new drug aims to stop psychosis from returning
Disease control Recruiting nowThis study tests an experimental drug called KarXT to see if it can prevent the return of psychosis (hallucinations, delusions) in people with Alzheimer's disease. About 410 participants aged 55-90 will receive either KarXT or a placebo for 38 weeks. The main goal is to see if th…
Matched conditions: PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE
Phase: PHASE3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Disease control
Last updated May 26, 2026 11:59 UTC
-
New hope for Alzheimer's psychosis: Long-Term drug safety trial underway
Symptom relief Recruiting nowThis study is testing the long-term safety of an investigational drug called ML007C-MA for people with Alzheimer's disease who experience hallucinations and delusions. It is an open-label extension study, meaning all participants will receive the drug, and it lasts for 52 weeks. …
Matched conditions: PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE
Phase: PHASE2 • Sponsor: MapLight Therapeutics • Aim: Symptom relief
Last updated May 26, 2026 12:28 UTC
-
Could this pill ease Alzheimer's hallucinations? major trial underway
Symptom relief Recruiting nowThis study tests an experimental drug called KarXT to see if it can safely reduce hallucinations and delusions in people with Alzheimer's disease. About 500 adults aged 55 to 90 with mild to severe Alzheimer's and moderate to severe psychosis will receive either KarXT or a placeb…
Matched conditions: PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE
Phase: PHASE3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Symptom relief
Last updated May 26, 2026 12:07 UTC
-
New hope for Alzheimer's psychosis: drug trial targets hallucinations
Symptom relief Recruiting nowThis study tests an experimental drug called ML-007C-MA to see if it can reduce hallucinations and delusions in people with Alzheimer's disease. About 300 participants aged 55 to 90 will receive either the drug or a placebo. The goal is to improve symptoms without aiming to cure …
Matched conditions: PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE
Phase: PHASE2 • Sponsor: MapLight Therapeutics • Aim: Symptom relief
Last updated May 22, 2026 14:05 UTC
-
New pill aims to calm Alzheimer's psychosis in landmark trial
Symptom relief Recruiting nowThis study tests an experimental drug called ITI-1284 to see if it can safely reduce psychosis symptoms like hallucinations and delusions in people with Alzheimer's disease. About 370 participants will receive either the drug or a placebo, and researchers will measure changes in …
Matched conditions: PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE
Phase: PHASE2 • Sponsor: Intra-Cellular Therapies, Inc. • Aim: Symptom relief
Last updated May 20, 2026 11:57 UTC